Clinical Trial

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2019-07-31; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2026-04-23
Status change: Not Yet Recruiting → Recruiting 2020-07-09
Trial Details
NCT Number NCT04042831
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Enrollment 32 participants
Start Date 2020-06-24
Primary Completion 2025-03-12 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15